ArticleEuropean urology2018

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.

Mitchell G Lawrence et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.